Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 5, 2005, Pages 435-441

  Sierra, Cristina ^a   De La Sierra, Alejandro ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Angiotensin receptor blockers; Anti atherosclerotic properties; Antihypertensive agents; Cardiovascular protection; Vascular effects

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANDESARTAN; CAPTOPRIL; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; GELATINASE B; HYDROCHLOROTHIAZIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IRBESARTAN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN; N(G) METHYLARGININE; NITRENDIPINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SELECTIN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; DIABETIC NEPHROPATHY; DRESSLER SYNDROME; DRUG MECHANISM; ENDOTHELIUM; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW;

EID: 23844436724     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000174397.59100.89     Document Type: Review

References (43)

1. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360:752-760.
2. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
3. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
4. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587.
5. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
6. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40:1414-1421.
7. McMurray JJV, Östergen J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771.
8. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-776.
9. Yusuf S, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Preserved trial. Lancet 2003; 362:777-781.
10. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure. Lancet 2003; 362:759-766.
11. Breener BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
13. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
14. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106:672-678.
15. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961. The first study that directly compared ARB with ACE inhibition in patients with renal disease.
16. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124
17. [Erratum in: Lancet 2003; 361:1230]. One of the first studies that were intended to demonstrate the effects of the addition of ARBs to ACE inhibitors in patients with renal disease.
18. Dahlof B, Dvereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
19. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-888.
20. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031. The largest study reported to date comparing an ARB with a calcium antagonist in high-risk hypertensive patients. Although no differences in the primary objective were observed between treatments, the results clearly indicated that early blood-pressure control is needed in order to protect high-risk patients against cardiovascular disease.
21. Schrader J, Lüders S, Kulchewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stoke 2005; 36:1218-1224. This is the first study of ARBs on secondary prevention of stroke. Eprosartan is clearly superior to nitrendipine in preventing cardiovascular disease in hypertensive subjects with a previous stroke.
22. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
23. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
24. Devereux RB, Dahlöf B, Gerdts E, et al. Regression of left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial. Circulation 2004; 110:1456-1462.
25. Schächinger V, Britten M, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
26. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104:191-196.
27. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-1659.
28. Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003; 60:191-196.
29. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
30. Blankenberg S, Rupprecht HJ, Bickel C, et al., for the AtheroGene Investigators. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336-1342.
31. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apo-E-deficient mice. Circulation 2001; 103:448-454.
32. Kon K, Yeal J, Hwan S, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42:905-910.
33. Fliser D, Buchholz K, Haller H, for the European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107. This study shows that treatment with the ARB olmesartan decreases several vascular inflammatory markers.
34. Rahman ST, Lauten WB, Khan QA, et al. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol 2002; 89:686-690.
35. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-κB, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003; 88:4496-4501.
36. Park JB, Sciffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19:921-930.
37. Rizzoni D, Porteri E, Boari GEM, et al. Prognostic significance of small artery structure in hypertension. Circulation 2003; 108:2230-2235.
38. Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 2005; 45:1-7.
39. Ciulla M, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Circulation 2004; 110:552-557.
40. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969. An interesting study performed in a long-term cohort study about the development of diabetes during antihypertensive treatment. It clearly shows the prognostic importance of new-onset diabetes developed during hypertension follow up.
41. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905-912.
42. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22:2253-2261. An excellent review about the mechanisms by which ACE inhibitors and ARBs improve insulin sensitivity and decrease the risk for type 2 diabetes.
43. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-γ activity. Circulation 2004; 109:2054-2057. One of the first experimental studies that showed another action of ARBs: peroxisome proliferator-activated receptor-γ agonist activity.